84 completed, 20 unknown, 13 terminated, 6 recruiting. 63 Phase 2, 22 Not applicable, 19 Phase 1, 13 Phase 3, 5 Phase 4.
Follow Nonalcoholic Steatohepatitis: new trials by email Literature Review of Nonalcoholic Steatohepatitis trials Research Report on Nonalcoholic Steatohepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Tesamorelin, Placebo, Standardized lifestyle counseling - Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-03-19 |
| Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis Embospheres Microspheres - Obesity, Weight Loss | Not applicable | Not yet recruiting | Keith Pereira, MD: | 8 | 2025-12-01 | 2025-07-28 |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis Denifanstat, Placebo - MASH, NASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH denifanstat, Placebo - MASLD, MASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Efinopegdutide, Placebo - Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 85 | 2024-07-12 | 2026-09-21 |
| ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) ALG-055009, Placebo - NASH, MASH | Phase 2 | Completed | Aligos Therapeutics | 102 | 2024-04-01 | 2025-02-17 |
| Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis HU6, Placebo - Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Active not recruiting | Rivus Pharmaceuticals, Inc. | 219 | 2023-09-05 | 2025-04-18 |
| Conditionally Increased Output (CIO) Enhanced Ultrasound System GE ultrasound system with increased acoustic output settings - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Not applicable | Completed | Massachusetts General Hospital | 24 | 2023-06-30 | 2025-05-23 |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Efinopegdutide, Semaglutide, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2023-06-23 | 2026-01-12 |
| Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis Rosuvastatin 20 Mg Oral Tablet, Coenzyme Q10 100 MG Oral Capsule - Nonalcoholic Steatohepatitis | Phase 3 | Unknown | Tanta University | 46 | 2023-06-01 | 2023-05-16 |
| Dose Escalation Study of Kylo-0603 in Healthy Subjects Kylo-0603 capsule, Placebo - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Kylonova (Xiamen) Biopharma co., LTD. | 132 | 2023-05-23 | 2024-10-09 |
| Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis Standard of care - Nonalcoholic Steatohepatitis | Recruiting | Virginia Commonwealth University | 240 | 2023-04-19 | 2026-04-02 | |
| Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans Synthroid, Placebo - Nonalcoholic Steatohepatitis, Liver Fibrosis | Phase 2 | Recruiting | VA Office of Research and Development | 128 | 2023-04-01 | 2026-02-19 |
| A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis AZD2693, Placebo - Nonalcoholic Steatohepatitis | Phase 2 | Completed | AstraZeneca | 220 | 2023-03-15 | 2025-10-28 |
| Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg) - Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver | Phase 1 | Completed | Oasis Pharmaceuticals, LLC | 24 | 2023-03-06 | 2025-06-25 |
| A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects B1344, Placebo - Nonalcoholic Steatohepatitis | Phase 1 | Unknown | Tasly Biopharmaceuticals Co., Ltd. | 56 | 2022-08-30 | 2022-12-19 |
| Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease AZD7503 Intervention - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 1 | Completed | AstraZeneca | 19 | 2022-08-12 | 2025-07-20 |
| Vitamin E Dosing Study Vitamin E, Placebo - Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 200 | 2022-08-05 | 2026-05-14 |
| Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis hydroxychloroquine - Nonalcoholic Steatohepatitis | Unknown | National Taiwan University Hospital | 150 | 2022-06-10 | 2023-03-02 | |
| A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH MSDC-0602K, Placebo - Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis | Phase 3 | Unknown | Cirius Therapeutics, Inc. | 1800 | 2022-06-01 | 2021-07-12 |
Showing 20 of 134. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (134) · Fatty Liver (17) · Liver Cirrhosis (11) · Obesity (11) · Diabetes Mellitus, Type 2 (10) · Fibrosis (6) · Insulin Resistance (6) · Liver Diseases (6) · Diabetes Mellitus (3) · Motor Activity (3) · Digestive System Diseases (2) · Hepatitis C (2) · Metabolic Syndrome (2) · Weight Loss (2) · Acquired Immunodeficiency Syndrome (1)
Digestive System Diseases (132) · Liver Diseases (128) · Fatty Liver (117) · Nutritional and Metabolic Diseases (31) · Pathological Conditions, Signs and Symptoms (29) · Metabolic Diseases (22) · Glucose Metabolism Disorders (19) · Pathologic Processes (18) · Endocrine System Diseases (15) · Nutrition Disorders (12) · Overnutrition (12) · Overweight (12) · Signs and Symptoms (12) · Body Weight (11) · Diabetes Mellitus (11)
Pioglitazone (5) · Pegbelfermin (4) · semaglutide (4) · cenicriviroc (3) · Diagnostic Imaging (2) · Dietary Supplements (2) · Liraglutide (2) · Losartan (2) · NRL972 (2) · Pentoxifylline (2) · Standard of Care (2) · TVB-2640 (2) · Vitamin E (2) · cilofexor (2) · firsocostat (2)
Gilead Sciences (6) · Bristol-Myers Squibb (5) · Merck Sharp & Dohme LLC (4) · Massachusetts General Hospital (3) · Tobira Therapeutics, Inc. (3) · University of California, San Diego (3) · AstraZeneca (2) · Catalysis SL (2) · Hadassah Medical Organization (2) · Intercept Pharmaceuticals (2) · Korea University Guro Hospital (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Norgine (2) · Northwestern University (2) · Pfizer (2)
United States (79) · Australia (17) · Canada (17) · France (16) · United Kingdom (16) · Israel (15) · Spain (15) · Germany (13) · Japan (13) · Puerto Rico (12) · Italy (11) · Poland (11) · South Korea (11) · Taiwan (11) · China (10)
Keith D Lindor, MD (2) · Kenneth Cusi, MD (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · An Tang, MD (1) · Anthony E Samir, MD, MPH (1) · Arun Sanyal, MD (1) · Arun Sanyal, MD, PhD (1) · Athan Kuliopulos, MD, PhD (1) · Benjamin Snyder (1)
PMID 30639779, PMID 30779990, PMID 31271665, PMID 32147362, PMID 33307033, PMID 33657443, PMID 36318027, PMID 36750244, PMID 15942443, PMID 17135584, PMID 17560678, PMID 17581899, PMID 18086506, PMID 18796671, PMID 19262374, PMID 19353360, PMID 19670459, PMID 20448542, PMID 20460906, PMID 21677329, PMID 21748765, PMID 21911884, PMID 22013734, PMID 22367009, PMID 22488764, PMID 23396737, PMID 23401313, PMID 23537027, PMID 23930163, PMID 24187469, PMID 24462005, PMID 24631112, PMID 24815326, PMID 25285192, PMID 25349724, PMID 25581263, PMID 25813773, PMID 26278654, PMID 26394161, PMID 26493259, PMID 26608256, PMID 26629307, PMID 26944023, PMID 27322798, PMID 27347680, PMID 27567998, PMID 29223443, PMID 29414684, PMID 29805116, PMID 30411081
2016 (5), 2017 (2), 2018 (2), 2019 (2), 2023 (1), I01CX002436 (1), P30CA060553 (1), R01DK088114 (1), R01DK110186 (1), R01DK113701 (1), R01DK120331 (1), R01DK129564 (1), R01DK129656 (1), R44DK101240 (1), U01DK061713 (1)